🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Cathie Wood's ARK ETFs adjust holdings, buying Roku, selling Tesla

Published 10/31/2024, 08:01 PM
NTRA
-
ROKU
-

Cathie Wood's ARK ETFs revealed their daily trades for Thursday, 31 October 2024, with a significant reshuffling of their holdings. The investment management firm, known for its focus on disruptive innovation, made notable transactions across various sectors, with an emphasis on technology and healthcare stocks.

The most substantial purchase of the day was in Roku Inc (NASDAQ:ROKU), with ARK buying a total of 308,892 shares across three of its funds, amounting to a total dollar value of $23,942,219. This move indicates a bullish stance on the streaming device company, which has seen its stock price fluctuate in recent months.

In the biotech sphere, ARK continued to invest heavily in Natera Inc (NASDAQ:NTRA), purchasing 131,972 shares for a total value of $16,724,812. This follows a pattern of consistent buying, suggesting ARK's confidence in the genetic testing company's growth prospects.

On the selling side, ARK divested a significant portion of its holdings in Block Inc (NYSE:SQ), formerly known as Square, shedding 243,549 shares for $17,849,706. This sale could be indicative of a strategic pivot or a response to recent market trends affecting the payments industry.

Another notable sale was of Palantir Technologies Inc (NYSE:NYSE:PLTR), with ARK selling 334,767 shares totaling $14,625,969. This decision comes amidst a backdrop of the data analytics firm's variable performance and potential adjustments in ARK's investment thesis.

Additionally, Roblox Corp (NYSE:RBLX) saw a reduction in ARK's stake, as 339,352 shares were sold for $14,639,645. The gaming platform has been a volatile stock, and ARK's sale might reflect a move to capitalize on recent price movements or rebalance its portfolio.

In the pharmaceutical sector, ARK sold 50,200 shares of Moderna Inc (NASDAQ:MRNA) for $2,746,944, possibly taking profits or reallocating funds following the biotech firm's rollercoaster ride since the onset of the pandemic.

Other trades included buying shares of Beam Therapeutics Inc (NASDAQ:BEAM), Recursion Pharmaceuticals Inc (NASDAQ:RXRX), and Tempus AI Inc (NYSE:TEM), while selling shares of Nurix Therapeutics Inc (NASDAQ:NRIX) and Tesla Inc (NASDAQ:TSLA).

Overall, ARK's trading activity reflects an ongoing strategy to invest in companies with transformative potential while remaining responsive to market dynamics. Investors closely watch these trades for insights into Cathie Wood's outlook on the evolving landscape of innovative industries.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.